profit from every $100 of sales.
$0$100
Pacira BioSciences
$36.46+0.00% today
+54.4% in 1 year
1-year low $19.161-year high $36.49
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $206.88 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pacira BioSciences sold, what it kept, and what it did with the cash.
Sales went from $667 million in 2022 to $726 million in 2025, with $7.03 million of profit last year.
SalesProfit
Pacira BioSciences handed back more cash to shareholders than it generated last year.
Buybacks $148M
Free cash flow 2025$137M
Bought back its own shares$148M
Paid as dividends–
Cash vs. debt$159M vs. $418M
Pacira BioSciences vs. similar companies
Pacira BioSciences grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pacira BioSciences | 206.9× · Very expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Pacira BioSciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 667 | 675 | 701 | 726 | |
| 468 | 490 | 531 | 577 | |
| 60 | 88 | 90 | 19 | |
| 140 | 155 | 29 | 123 | |
| 16 | 42 | -100 | 7 | |
| 0.34 | 0.89 | -2.15 | 0.16 | |
| 70.1% | 72.6% | 75.7% | 79.4% | |
| 9.0% | 13.0% | 12.8% | 2.6% | |
| 2.4% | 6.2% | -14.2% | 1.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,681 | 1,574 | 1,554 | 1,265 |
| Cash | 104 | 153 | 277 | 159 |
| Total debt | 763 | 586 | 639 | 418 |
| Total liabilities | 906 | 704 | 775 | 572 |
| 775 | 870 | 778 | 693 | |
| 47 | 52 | 46 | 45 | |
| 2.5% | 4.3% | -2.8% | 2.2% | |
| 2.1% | 4.8% | -12.8% | 1.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 145 | 155 | 189 | 152 | |
| 30 | 15 | 11 | 15 | |
| 115 | 139 | 179 | 137 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 25 | 148 | |
| 48 | 48 | 51 | 58 |
Valuation
- 206.9×
- –
- –
- 1.5×
- 2.0×
- 10.6×
- 14.0×
- 9.4%
- 0.5%
- 0.0%
Profitability
- 79.4%
- 2.6%
- 1.0%
- 16.1%
- 0.8%
- -0.0%
- 0.7%
- 0.4%
- 2.1%
- 16.3%
Growth
- +2.9%
- −22.2%
- −23.5%
- –
- +0.2%
Financial health
- 2.3×
- 0.63
- 34.0%
- 1.5×
- 4.73
- 3.35
- 0.61
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 952
Bottom 31%of 884
Bottom 2%of 601
Bottom 24%of 886
Top 9%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 0.60 | 0.61 | −1.6% |
| Feb 26, 2026 | 0.57 | 0.85 | −32.9% |
| Nov 6, 2025 | 0.70 | 0.65 | +7.7% |
| Aug 5, 2025 | 0.74 | 0.72 | +2.8% |
| May 8, 2025 | 0.62 | 0.57 | +8.8% |
| Feb 27, 2025 | 0.91 | 0.78 | +16.7% |
| Nov 6, 2024 | 0.79 | 0.72 | +9.7% |
| Jul 30, 2024 | 0.89 | 0.73 | +21.9% |
News
Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira dealSeeking Alpha · Nov 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
58No pass
Philip Fisher
35No pass
Peter Lynch
21No pass
Joel Greenblatt
3No pass
Charlie Munger
31No pass
Terry Smith
32No pass
Questions about Pacira BioSciences
Is Pacira BioSciences a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pacira BioSciences AI analysis
What does Pacira BioSciences do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. It is in Drug Manufacturers - Specialty & Generic.
Does Pacira BioSciences pay a dividend?
No. Pacira BioSciences does not pay a dividend at the moment; in 2025 it returned $148 million to shareholders by buying back its own shares.
Is Pacira BioSciences stock halal?
Yes. Pacira BioSciences passes our halal screen: its business is permitted and its debt is 29% of its market value, under the 30% limit. How we check
How has Pacira BioSciences stock done over the past year?
Up 54.4% over the past twelve months, to $36.46. It traded between $19.16 and $36.49, close to its high.
Who are Pacira BioSciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Pacira BioSciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.